Pirofsky B, Reid R H, Bardana E J, Baker R L
Neurology. 1979 Jan;29(1):112-6. doi: 10.1212/wnl.29.1.112.
The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in 10 patients with myasthenia gravis. All subjects had far-advanced, debilitating disease poorly responsive to anticholinesterase therapy. Prolonged, low-dose ATG therapy was used, with 1.0 to 2.6 gm ATG protein administered intramuscularly over a 28- to 73-day period. Therapeutic responses of varying degrees were noted in 8 of 10 patients. Completion of a course of ATG treatment and discontinuation of the drug did not lead to acute relapse. Follow-up examinations for over 5 years have been maintained. A mean remission period of approximately 2 years was observed. This therapy deserves further evaluation; subjects with progressive myasthenia gravis despite prior thymectomy may represent ideal candidates.
对10例重症肌无力患者评估了山羊抗人胸腺细胞抗血清球蛋白（ATG）的治疗效果。所有受试者病情都已发展到晚期，身体衰弱，对抗胆碱酯酶治疗反应不佳。采用了长时间、低剂量的ATG治疗，在28至73天的时间内肌肉注射1.0至2.6克ATG蛋白。10例患者中有8例出现了不同程度的治疗反应。完成一个疗程的ATG治疗并停药后未导致急性复发。已进行了超过5年的随访检查。观察到平均缓解期约为2年。这种疗法值得进一步评估；尽管之前做过胸腺切除术但仍患有进行性重症肌无力的患者可能是理想的候选对象。
